Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

December 15, 2009; 73 (24) Editorials

APOE ε4 and bapineuzumab

Infusing pharmacogenomics into Alzheimer disease therapeutics

Dan Kaufer, Sam Gandy
First published November 18, 2009, DOI: https://doi.org/10.1212/WNL.0b013e3181c6784a
Dan Kaufer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam Gandy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
APOE ε4 and bapineuzumab
Infusing pharmacogenomics into Alzheimer disease therapeutics
Dan Kaufer, Sam Gandy
Neurology Dec 2009, 73 (24) 2052-2053; DOI: 10.1212/WNL.0b013e3181c6784a

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
678

Share

  • Article
  • Info & Disclosures
Loading

Article Information

vol. 73 no. 24 2052-2053
DOI: 
https://doi.org/10.1212/WNL.0b013e3181c6784a
PubMed: 
19923549

Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published November 18, 2009.

Article Versions

  • Previous version (November 18, 2009 - 12:51).
  • You are viewing the most recent version of this article.
Copyright & Usage: 
© 2009

Author Disclosures

    1. Dan Kaufer, MD and
    2. Sam Gandy, MD, PhD
  1. Dan Kaufer, MD and
  2. Sam Gandy, MD, PhD
  1. From the Department of Neurology (D.K.), University of North Carolina, Chapel Hill; Departments of Neurology and Psychiatry (S.G.), Mount Sinai School of Medicine, New York; and James J. Peters Veterans Affairs Medical Center (S.G.), Bronx, NY.
  1. Address correspondence and reprint requests to Dr. Dan Kaufer, CB 7025, 3129 POB, 170 Manning Drive, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; kauferd{at}neurology.unc.edu
View Full Text

Article usage

Article usage: November 2009 to March 2023

AbstractFullPdfSource
Nov 200900138Highwire
Dec 20090200182Highwire
Jan 201004962Highwire
Feb 201002432Highwire
Mar 201002818Highwire
Apr 201002012Highwire
May 2010077Highwire
Jun 201001110Highwire
Jul 2010086Highwire
Aug 20100610Highwire
Sep 20100108Highwire
Oct 20100114Highwire
Nov 2010032Highwire
Dec 20100133Highwire
Jan 20110135Highwire
Feb 2011094Highwire
Mar 20110145Highwire
Apr 20110121Highwire
May 2011011Highwire
Jun 2011033Highwire
Jul 2011055Highwire
Aug 2011064Highwire
Sep 20110106Highwire
Oct 2011375Highwire
Nov 2011353Highwire
Dec 2011111Highwire
Jan 2012200Highwire
Feb 2012103325Highwire
Mar 20121756Highwire
Apr 20121744Highwire
May 20121111Highwire
Jun 20121120Highwire
Jul 20122754Highwire
Aug 20121622Highwire
Sep 2012500Highwire
Oct 2012611Highwire
Dec 2012011Highwire
Jan 2013005Highwire
Feb 20130915Highwire
Mar 2013014Highwire
Apr 2013011Highwire
May 2013011Highwire
Jun 2013522Highwire
Jul 2013100Highwire
Aug 2013303Highwire
Sep 2013300Highwire
Oct 20131530Highwire
Nov 2013521Highwire
Dec 2013511Highwire
Jan 20141839Highwire
Feb 201436412Highwire
Mar 20142004Highwire
Apr 2014500Highwire
May 2014700Highwire
Jun 2014401Highwire
Jul 2014800Highwire
Aug 2014701Highwire
Sep 2014110Highwire
Oct 20142014Highwire
Nov 2014703Highwire
Dec 20141704Highwire
Jan 2015901Highwire
Feb 2015100Highwire
Mar 20151011Highwire
Apr 20151200Highwire
May 20151300Highwire
Jun 2015812Highwire
Jul 20151401Highwire
Aug 2015812Highwire
Sep 20151210Highwire
Oct 20151031Highwire
Nov 2015700Highwire
Dec 20151700Highwire
Jan 2016300Highwire
Feb 20161600Highwire
Mar 2016832Highwire
Apr 2016520Highwire
May 20161200Highwire
Jun 20161311Highwire
Jul 2016900Highwire
Aug 20161211Highwire
Sep 20161010Highwire
Oct 20162000Highwire
Nov 2016800Highwire
Dec 2016900Highwire
Jan 20171400Highwire
Feb 20171210Highwire
Mar 2017800Highwire
Apr 20171400Highwire
May 20171300Highwire
Jun 2017902Highwire
Jul 2017800Highwire
Aug 20171100Highwire
Sep 2017611Highwire
Oct 2017800Highwire
Nov 2017500Highwire
Dec 20171300Highwire
Jan 20181130Highwire
Feb 20182010Highwire
Mar 20182400Highwire
Apr 20181700Highwire
May 20181301Highwire
Jun 20182400Highwire
Jul 20183022Highwire
Aug 20181100Highwire
Sep 2018900Highwire
Oct 20182210Highwire
Nov 20182700Highwire
Dec 20181400Highwire
Jan 20192700Highwire
Feb 20192500Highwire
Mar 2019900Highwire
Apr 2019510Highwire
May 20191100Highwire
Jun 2019700Highwire
Jul 20191401Highwire
Aug 20191700Highwire
Sep 2019600Highwire
Oct 20191400Highwire
Nov 20192010Highwire
Dec 2019811Highwire
Jan 2020900Highwire
Feb 2020800Highwire
Mar 2020910Highwire
Apr 2020101Highwire
May 20201100Highwire
Jun 2020800Highwire
Jul 2020500Highwire
Aug 2020400Highwire
Sep 2020700Highwire
Oct 2020900Highwire
Nov 2020610Highwire
Dec 20201200Highwire
Jan 20211000Highwire
Feb 2021600Highwire
Mar 20211300Highwire
Apr 20212000Highwire
May 20211900Highwire
Jun 2021800Highwire
Jul 20212600Highwire
Aug 20212000Highwire
Sep 2021711Highwire
Oct 2021900Highwire
Nov 2021900Highwire
Dec 20212730Highwire
Jan 20221400Highwire
Feb 20221600Highwire
Mar 2022700Highwire
Apr 20221600Highwire
May 2022900Highwire
Jun 2022800Highwire
Jul 20221501Highwire
Aug 2022211Highwire
Sep 20221222Highwire
Oct 2022400Highwire
Nov 20221800Highwire
Dec 2022700Highwire
Jan 20232100Highwire
Feb 20231200Highwire

Cited By...

  • 18 Citations
  • Google Scholar

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Articles
    A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
    S. Salloway, R. Sperling, S. Gilman et al.
    Neurology, November 18, 2009
  • Articles
    Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy
    A. van der Walt, J. Stankovich, M. Bahlo et al.
    Neurology, September 28, 2009
  • Article
    APOE ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia
    Saira Saeed Mirza, Usman Saeed, Jo Knight et al.
    Neurology, October 01, 2019
  • Article
    APOE polymorphisms influence longitudinal lipid trends preceding intracerebral hemorrhage
    Chia-Ling Phuah, Miriam R. Raffeld, Alison M. Ayres et al.
    Neurology: Genetics, June 23, 2016
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise